Clinchoice
Clinchoice is recorded as a service provider in 30 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 30 trials · Latest update first
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Sponsor Alkermes Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Sponsor Alkermes Inc.
- Start (EU)
- Latest update
- Estimated end
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
Sponsor Eikon Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR
Sponsor Alkeus Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1
Sponsor Alkermes Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
Sponsor Kardigan Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low Grade (LG) Nonmuscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (UTOPIA)
Sponsor Urogen Pharma Ltd.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Sponsor Alkermes Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
Sponsor Immunocore Limited
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The study randomized 378 patients at 58 sites in 14 countries.
- Tebentafusp required at least 16 hours of inpatient monitoring after dosing on Cycle 1 Days 1, 8, and 15 because of anticipated cytokine release syndrome.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).
Sponsor Kardigan Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Sponsor 89bio Inc.
- Start (EU)
- Latest update
- Estimated end
A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006)
Sponsor Eikon Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)
Sponsor Regentree LLC
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® IM versus Placebo IM as an Enhancer Adjunctive to Antidepressant Treatment in Major Depression Disorder Patients Who have not Experienced Sufficient Symptoms Improvement Despite Antidepressant Treatment
Sponsor Mylan Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® Tablet versus Placebo Tablet on top of Adjunctive Antidepressant Treatment in Patients with Major Depression Disorder with Mild to Moderate Symptoms
Sponsor Mylan Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
Sponsor Day One Biopharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Clinchoice?
The 2026-10-09 snapshot links Clinchoice to 30 distinct CTIS trials. Recorded services include Statistical analysis, Data management, Safety reporting & pharmacovigilance, Clinical monitoring, among 16 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Clinchoice?
The most frequently recorded therapeutic areas are Neurology, Solid Tumor Oncology, Ophthalmology, Cardiology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Clinchoice conducted?
The linked trials record locations in 24 countries, including Spain, Italy, France, Belgium, Germany. These are trial locations, not confirmed office locations or countries where Clinchoice delivered services.
What can this page tell me about Clinchoice's trial experience?
Browse 30 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 6 recorded name variants under Clinchoice. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- ClinChoice
- ClinChoice Inc
- ClinChoice, Inc.
- Clinchoice Inc.
- Clinchoice Limited
- Clinchoice S.r.l.